Beneficial electrophysiological effects of trimetazidine in patients with postischemic chronic heart failure

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 15, Issue 1, 2010, Pages 24-30

  Cera, Michela ^a   Salerno, Anna ^a   Fragasso, Gabriele ^a   Montanaro, Claudia ^a   Gardini, Chiara ^a   Marinosci, Giovanni ^a   Arioli, Francesco ^a   Spoladore, Roberto ^a   Facchini, Alberto ^a   Godino, Cosmo ^a   Margonato, Alberto ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Electrophysiological effect; Heart failure; Tpeak Tend dispersion; Trimetazidine; Ventricular repolarization

Indexed keywords

CALCIUM; MAGNESIUM; POTASSIUM; SODIUM; TRIMETAZIDINE;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CARDIAC PATIENT; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HEART ATRIUM; HEART DEPOLARIZATION; HEART EJECTION FRACTION; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART REPOLARIZATION; HUMAN; MAGNESIUM BLOOD LEVEL; MALE; P WAVE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RR INTERVAL; SODIUM BLOOD LEVEL; T WAVE; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANTISOCIAL PERSONALITY DISORDER; ARRHYTHMIAS, CARDIAC; CHRONIC DISEASE; ELECTROCARDIOGRAM PATTERN; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RISK FACTORS; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 76649115289     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248409356431     Document Type: Article

References (31)

1. Antzelevitch C. Role of spatial dispersion of repolarization in inherited and acquired sudden cardiac death syndromes. Am J Physiol Heart Circ Physiol. 2007 ; 293 (4). H2024 - H2038.
2. Hohnloser SH Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management. Am J Cardiol. 1997 ; 80 (8A). 82G - 89G.
3. Antzelevitch C. Drug-induced spatial dispersion of repolarization. Cardiol J. 2008 ; 15 (2). 100-121.
4. Wei K., Dorian P., Newman D., Langer A. Association between QT dispersion and autonomic dysfunction in patients with diabetes mellitus. J Am Coll Cardiol. 1995 ; 26 (4). 859-863.
5. Fei L., Goldman JH, Prasad K., et al. QT dispersion and RR variations on 12-lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy. Eur Heart J. 1996 ; 17 (2). 258-263.
6. Linker NJ, Colonna P., Kekwick CA, Till J., Camm AJ, Ward DE Assessment of QT dispersion in symptomatic patients with congenital long QT syndromes. Am J Cardiol. 1992 ; 69 (6). 634-638.
7. Schwartz PJ, Wolf S. QT interval prolongation as predictor of sudden death in patients with myocardial infarction. Circulation. 1978 ; 57 (6). 1074-1077.
8. Day CP, McComb JM, Campbell RW QT dispersion in sinus beats and ventricular extrasystoles in normal hearts. Heart. 1992 ; 67 (1). 39-41.
9. Antzelevitch C., Shimizu W., Yan GX. The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol. 1999 ; 10 (8). 1124-1152.
10. Yan G. -X, Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation. 1998 ; 98 (18). 1928-1936. (Pubitemid 28509291)
11. Roithinger FX, Karch MR, Steiner PR, SippensGroenewegen A., Lesh MD The spatial dispersion of atrial refractoriness and atrial fibrillation vulnerability. J Interv Card Electrophysiol. 1999 ; 3 (4). 311-319.
12. Michelucci A., Bagliani G., Colella A., et al. P wave assessment: state of the art update. Card Electrophysiol Rev. 2002 ; 6 (3). 215-220.
13. Brottier L., Barat JL, Combe C., Boussens B., Bonnet J., Bricaud H. Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur Heart sof trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol. 1998 ; 82 (7). 898-901.
14. Fragasso G., Piatti P., Monti L., Palloshi A., Setola E., Puccetti P. Short- and long-term beneficial effects of partial free fatty acid inhibition in diabetic patients with ischemic dilated cardiomyopathy. Am Heart J. 2003 ; 146 (5). E1 - E8.
15. Fragasso G., Palloshi A., Puccetti P., et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol. 2006 ; 48 (5). 992-998.
16. Fantini E., Athias P., Demaison L., Grynberg A. Protective effects of trimetazidine on hypoxic cardiac myocytes from the rat. Fundam Clin Pharmacol. 1997 ; 11 (5). 427-439.
17. Gunes Y., Tuncer M., Guntekin U., Akdag S., Gumrukcuoglu H. The effects of trimetazidine on p-wave duration and dispersion in heart failure patients. Pacing Clin Electrophysiol. 2009 ; 32 (2). 239-244.
18. Castro Hevia J., Antzelevitch C., Torns Bárzaga F., et al. Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol. 2006 ; 47 (9). 1828-1834.
19. Fantini E., Demaison L., Sentex E., Grynberg A., Athias P. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol. 1994 ; 26 (8). 949-958.
20. Fragasso G., De Cobelli F., Perseghin G., et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J. 2006 ; 27 (8). 942-948.
21. Fragasso G. Inhibition of free fatty acids metabolism as a therapeutic target in patients with heart failure. Int J Clin Pract. 2007 ; 61 (4). 603-610.
22. Xia Y., Liang Y., Kongstad O., et al. In vivo validation of the coincidence of the peak and end of the T wave with full repolarization of the epicardium and endocardium in swine. Heart Rhythm. 2005 ; 2 (2). 162-169.
23. Opthof T., Coronel R., Wilms-Schopman FJG, et al. Dispersion of repolarization in canine ventricle and the electrocardiographic T wave: Tp-e interval does not reflect transmural dispersion. Heart Rhythm. 2007 ; 4 (3). 341-348.
24. Milberg P., Reinsch N., Wasmer K., et al. Transmural dispersion of repolarization as a key factor of arrhythmogenicity in a novel intact heart model of LQT3. Cardiovasc Res. 2005 ; 65 (2). 397-404.
25. Shimizu M., Ino H., Okeie K., et al. T-peak to T-end interval may be a better predictor of high-risk patients with hypertrophic cardiomyopathy associated with a cardiac troponin I mutation than QT dispersion. Clin Cardiol. 2002 ; 25 (7). 335-339.
26. Papadopoulos CL, Kanonidis IE, Kotridis PS, et al. The effect of trimetazidine on reperfusion arrhythmias in acute myocardial infarction. Int J Cardiol. 1996 ; 55 (2). 137-142.
27. Ulgen MS, Akdemir O., Toprak N. The effects of trimetazidine on heart rate variability and signal-averaged electrocardiography in early period of acute myocardial infarction. Int J Cardiol. 2001 ; 77 (2-3). 255-262. (Pubitemid 32162118)
28. Kountouris E., Pappa E., Pappas K., et al. Metabolic management of coronary heart disease: adjunctive treatment with trimetazidine decreases QT dispersion in patients with a first acute myocardial infarction. Cardiovasc Drugs Ther. 2001 ; 15 (4). 315-321.
29. Yildirir A., Sade E., Tokgozoglu L., Oto A. The effects of chronic carvedilol therapy on QT dispersion in patients with congestive heart failure. Eur J Heart Fail. 2001 ; 3 (6). 717-721.
30. Coumel P., Maison-Blanche P., Badilini F. Dispersion of ventricular repolarization reality ? illusion? significance? Circulation. 1998 ; 97 (25). 2491-2493.
31. Kautzner J., Yi G., Camm AJ, Malik M. Short-and long-term reproducibility of QT, QTc, and QT dispersion measurement in healthy subjects. Pacing Clin Electrophysiol. 1994 ; 17 (5 pt 1). 928-937.